Northern Trust Corp Has $156.12 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Share on StockTwits

Northern Trust Corp trimmed its stake in Hologic, Inc. (NASDAQ:HOLX) by 0.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,251,174 shares of the medical equipment provider’s stock after selling 25,404 shares during the period. Northern Trust Corp owned about 1.22% of Hologic worth $156,121,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. McGuire Investment Group LLC increased its holdings in Hologic by 20.6% in the second quarter. McGuire Investment Group LLC now owns 96,190 shares of the medical equipment provider’s stock valued at $4,619,000 after purchasing an additional 16,446 shares during the period. Fox Run Management L.L.C. acquired a new stake in Hologic during the 2nd quarter worth about $576,000. Toronto Dominion Bank grew its holdings in Hologic by 17.5% during the 1st quarter. Toronto Dominion Bank now owns 192,929 shares of the medical equipment provider’s stock worth $9,336,000 after acquiring an additional 28,706 shares during the period. Geode Capital Management LLC grew its holdings in Hologic by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock worth $156,146,000 after acquiring an additional 190,788 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in Hologic by 21.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 7,166 shares of the medical equipment provider’s stock worth $347,000 after acquiring an additional 1,276 shares during the period. Institutional investors and hedge funds own 95.20% of the company’s stock.

Shares of Hologic stock traded up $0.34 during mid-day trading on Thursday, hitting $49.89. 67,328 shares of the stock were exchanged, compared to its average volume of 1,725,627. Hologic, Inc. has a 12 month low of $37.47 and a 12 month high of $52.19. The company has a 50-day simple moving average of $49.61 and a 200 day simple moving average of $47.44. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.11 and a current ratio of 1.57. The company has a market capitalization of $13.25 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.23 and a beta of 0.78.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.02. Hologic had a negative net margin of 0.89% and a positive return on equity of 27.95%. The firm had revenue of $852.40 million for the quarter, compared to analysts’ expectations of $836.91 million. During the same quarter last year, the firm earned $0.58 EPS. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 2.44 EPS for the current year.

Several analysts have recently commented on HOLX shares. Canaccord Genuity restated a “hold” rating and issued a $52.00 target price on shares of Hologic in a research note on Thursday, August 1st. BTIG Research restated a “buy” rating and issued a $52.00 target price on shares of Hologic in a research note on Thursday, August 1st. Stifel Nicolaus raised their target price on Hologic from $43.00 to $48.00 and gave the company a “hold” rating in a research note on Monday, August 5th. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research note on Friday, August 16th. Finally, BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. Hologic currently has an average rating of “Hold” and an average price target of $49.44.

In related news, insider Peter J. Valenti III sold 7,766 shares of Hologic stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total value of $381,621.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $48.77, for a total transaction of $9,480,692.92. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Different Types of Derivatives

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.